UNSPSC 51141568: Morsuximide

This classification denotes an anticonvulsant agent with the molecular formula C16H20N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57G776P4EJ, chemically known as 2,5-pyrrolidinedione, 3-methyl-1-(4-morpholinylmethyl)-3-phenyl- (9ci) but generally known as morsuximide, which bears US NIH Compound Identifier 71165. European Medicines Agency schedules Morsuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09072MIG.

UNSPSC 51141568 Morsuximide, a Commodity code, nominally covers a specific anticonvulsant medication, but recent state and local solicitation activity shows little alignment with this narrow pharmaceutical definition. The code has recorded minimal recent activity; instead, the tagged opportunities reflect broader pharmaceutical procurement patterns—naloxone distribution, direct-to-manufacturer prescription programs, and multi-source generic drug and over-the-counter product contracting. State and local buyers under this code are health departments, human services commissions, and cooperative purchasing alliances that manage pharmaceutical supply chains for public health initiatives, employee benefit programs, and community health delivery. The actual work being solicited spans emergency response supplies (naloxone kits), pharmacy benefit program innovation (direct manufacturer relationships), and commodity generic pharmaceutical distribution through established wholesale channels with strict manufacturing compliance, pricing transparency, and insurance requirements.

Recent activity concentrates in Florida and Texas, with multi-state cooperative participation spanning Minnesota and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to its Community Health Building, responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, a preliminary market-intelligence phase preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with responses due March 26, 2026, requiring vendor compliance with cGMP and Drug Supply Chain Security Act standards, fixed pricing models, and performance penalties for non-compliance. The code shows material activity but chiefly as a catch-all for pharmaceutical-adjacent procurements rather than morsuximide-specific demand.